Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Parmax Pharma's Pre-Tax Income for the
three
months ended in Mar. 2026 was ₹-22.7 Mil. Parmax Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹33.1 Mil. Therefore, Parmax Pharma's pretax margin for the quarter that ended in Mar. 2026 was -68.55%.
The historical rank and industry rank for Parmax Pharma's Pretax Margin % or its related term are showing as below:
BOM:540359'
s Pretax Margin % Range Over the Past 10 Years
Min: -51.17 Med: 0.3 Max: 4.61
Current: -48.27
BOM:540359's Pretax Margin % is ranked worse than 85.92% of 959
companies
in the Drug Manufacturers industry
Industry Median: 7.29
vs BOM:540359: -48.27
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Parmax Pharma Pretax Margin % Related Terms
Parmax Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Parmax Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540359 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parmax Pharma Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Parmax Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parmax Pharma (BOM:540359) has a Pretax Margin % of -68.55% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Parmax Pharma and its competitors. According to the industry distribution chart, Parmax Pharma ranks #824 out of 959 companies in the Drug Manufacturers industry, placing it in the top 85.9%.
Is Parmax Pharma's Pretax Margin % too high?
Parmax Pharma's current Pretax Margin % is -68.55%. Based on the distribution chart, Parmax Pharma ranks #824 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Parmax Pharma has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Parmax Pharma's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Parmax Pharma ranks #824 out of 959 companies for Pretax Margin %. This places Parmax Pharma in the lower half of its industry. The industry median Pretax Margin % is 7.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.29, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Parmax Pharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parmax Pharma's current Pretax Margin % is -68.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parmax Pharma stock overvalued right now?
Based on GuruFocus' analysis, Parmax Pharma (BOM:540359) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹25.56, compared to a current price of ₹102.92 — trading 302.7% above its estimated fair value. The current Pretax Margin % is -68.55%. Parmax Pharma's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Parmax Pharma (BOM:540359), the current Pretax Margin % is -68.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Parmax Pharma (BOM:540359) Overvalued in 2026?
Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued.
The current stock price of ₹102.92 is trading 302.7% above its estimated GF Value™ of ₹25.56.
GuruFocus considers Parmax Pharma to be Significantly Overvalued.
Key valuation signals for BOM:540359:
Pretax Margin %: -68.55%
GF Value™: ₹25.56 vs. price of ₹102.92 (302.7% above fair value)
No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540359 has been successfully added to your 
